Publications by authors named "Katarzyna Orlewska"

10 Publications

  • Page 1 of 1

Impact of Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) on Treatment Cost of Multiple Sclerosis: Real-World Nationwide Study.

Value Health Reg Issues 2021 Apr 14;25:104-107. Epub 2021 Apr 14.

Medical University of Warsaw, Hematology, Oncology, and Internal Diseases, Warsaw, Poland. Electronic address:

Objectives: To provide real-world data on the impact of autologous hematopoietic stem cell transplantation (AHSCT) on treatment costs of patients with multiple sclerosis (MS) in Poland.

Methods: Medical data of 105 patients who underwent AHSCT in the years 2011 to 2016 were obtained from the National Health Fund (NHF) database. Treatment costs were calculated from the public payer's perspective per patient-year for the total available period as well as 12 months before and after AHSCT. The statistical analysis was performed using MATLAB 2016b.

Results: Mean treatment-related costs covered by the NHF per patient-year before and after the transplantation were €4314.9 and €1188.8 , respectively. The average cost of disease-modifying drugs per patient was reduced from €2497.9/year before to €65.3/year after AHSCT.

Conclusions: Although the initial cost of AHSCT is high, the costs involving AHSCT and post-AHSCT treatment could, according to our analysis, pay off in 3.9 years, when compared to the costs of disease-modifying drug therapy in aggressive MS. The study provides evidence that the AHSCT can lead to significant savings in treatment costs of aggressive MS from the public payer's perspective.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vhri.2020.10.008DOI Listing
April 2021

Impact of Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) on Treatment Cost of Multiple Sclerosis: Real-World Nationwide Study.

Value Health Reg Issues 2021 Apr 14;25:104-107. Epub 2021 Apr 14.

Medical University of Warsaw, Hematology, Oncology, and Internal Diseases, Warsaw, Poland. Electronic address:

Objectives: To provide real-world data on the impact of autologous hematopoietic stem cell transplantation (AHSCT) on treatment costs of patients with multiple sclerosis (MS) in Poland.

Methods: Medical data of 105 patients who underwent AHSCT in the years 2011 to 2016 were obtained from the National Health Fund (NHF) database. Treatment costs were calculated from the public payer's perspective per patient-year for the total available period as well as 12 months before and after AHSCT. The statistical analysis was performed using MATLAB 2016b.

Results: Mean treatment-related costs covered by the NHF per patient-year before and after the transplantation were €4314.9 and €1188.8 , respectively. The average cost of disease-modifying drugs per patient was reduced from €2497.9/year before to €65.3/year after AHSCT.

Conclusions: Although the initial cost of AHSCT is high, the costs involving AHSCT and post-AHSCT treatment could, according to our analysis, pay off in 3.9 years, when compared to the costs of disease-modifying drug therapy in aggressive MS. The study provides evidence that the AHSCT can lead to significant savings in treatment costs of aggressive MS from the public payer's perspective.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vhri.2020.10.008DOI Listing
April 2021

Probable genetic Creutzfeldt-Jakob Disease with rare E196K mutation.

Neurol Neurochir Pol 2021 2;55(1):113-114. Epub 2021 Feb 2.

Collegium Medicum, Jan Kochanowski University, Kielce, Poland.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5603/PJNNS.a2021.0009DOI Listing
April 2021

Glutathione S-transferases gene polymorphism influence on the age of diabetes type 2 onset.

BMJ Open Diabetes Res Care 2020 11;8(2)

Collegium Medicum, Jan Kochanowski University of Kielce, Kielce, Poland.

Introduction: Type 2 diabetes (T2D) is a multifactorial disease affecting mostly adults older than 40 years. The aim of the study was to examine gene polymorphism influence on the risk of T2D, especially in young adults.

Research Design And Methods: 200 diabetic patients and 221 healthy controls participated in this study. Three gene polymorphism have been analyzed: (single-nucleotide polymorphism IleVal), homozygous deletion of (null/null) and (null/null), using TaqMan real-time quantitative PCR.

Results: The distribution of examined polymorphisms was similar in patient group and control group. Statistically significant differences were demonstrated for the combination of and / genotypes between patients diagnosed before 40 years of age and healthy people (12.5% vs 0.9%, p=0.016). Moreover, all three examined gene polymorphism together (, and genotype) was observed in 12.5% of patients diagnosed before 40 years of age and in 0.5% of healthy individuals (p=0.013).

Conclusion: In conclusion, the results suggest that polymorphism may be one of the risk factors for developing T2D at a younger age than the T2D population average.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjdrc-2020-001773DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674104PMC
November 2020

Burden of cancer in Poland analysed using potential years of life lost.

Contemp Oncol (Pozn) 2020 13;24(1):13-16. Epub 2020 Mar 13.

Faculty of Medicine and Health Sciences, Jan Kochanowski University, Kielce, Poland.

Aim Of The Study: The aim was to assess the impact of the most frequent cancer-related causes of death in Poland by estimating the years of potential life lost (YPLL) and to compare different measures of the burden of cancer deaths on the population.

Material And Methods: Mortality rate, YPLL and mean YPLL were calculated for the 11 most frequently recorded cancer-related causes of death in Poland. YPLL were measured applying the up-to-date reference life tables proposed by the Institute for Health Metrics and Evaluation and used in the Global Burden of Disease study (GBD 2015). Absolute numbers of cancer deaths by site, gender and five-year age groups were obtained from the Polish National Cancer Registry (2015).

Results: In 2015 the total YPLL amounted to 1,990,457, with 23.6% from lung and bronchial cancer. Mean YPLL was 19.79 years and varied considerably according to tumour site (26.12 [brain] - 14.3 [prostate]). Three tumour sites (brain, ovarian and kidney) are positioned higher according to mean YPLL than according to YPLL percentage and mortality percentage.

Conclusions: Our results draw attention to the impact of cancer on society and individual patients. Addressing research efforts to prevention and/or treatment of major YPLL causes could result in a substantial impact on general life expectancy.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5114/wo.2020.93680DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265957PMC
March 2020

Cost-effectiveness of somatostatin analogues in the treatment of acromegaly.

Expert Rev Pharmacoecon Outcomes Res 2019 02 3;19(1):15-25. Epub 2018 Sep 3.

b Faculty of Medicine , Medical University of Warsaw , Warsaw , Poland.

Introduction: Somatostatin analogues (SSAs) are the largest contributor to the direct medical cost of acromegaly management worldwide. The aim of this review was to identify and report available evidence on the cost-effectiveness of SSAs in the treatment of acromegaly.

Areas Covered: A literature search on relevant papers published up to April 2018 was performed. A total of 22 eligible studies (10 full-text articles and 12 conference abstracts) conducted in 14 countries were included in the analysis. In majority of studies, modelling technique was the principal research method.

Expert Commentary: The results of cost-effectiveness analyses: 1) support published recommendations where SSAs are indicated as first-line medical treatment for patients with persistent disease after surgery or who are not eligible for surgery; 2) suggest that preoperative medical therapy with SSAs may be highly cost-effective in acromegalic patients with macroadenoma, in centres without optimal surgical results 3) indicate that in some countries pasireotide and pegvisomant appeared to be cost-effective or even dominant strategies in comparison to first-generation SSAs. The main limitation of economic evaluations was the lack of high-quality studies designed to directly compare various treatment strategies in acromegaly.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2018.1513330DOI Listing
February 2019

An ecological study of the link between the risk of most frequent types of cancer in Poland and socioeconomic variables.

Int J Public Health 2018 Sep 5;63(7):777-786. Epub 2018 Mar 5.

Faculty of Medicine and Health Sciences, The Jan Kochanowski University in Kielce, Al. IX Wieków Kielc 19, 25-317, Kielce, Poland.

Objectives: To assess the link between the risks of most frequent cancer sites in Poland and selected socioeconomic variables that potentially affect health outcomes throughout the life course.

Methods: This is a cross-sectional ecological study. Incidence of lung, breast, and colon cancer by voivodeships in 2014 was calculated based on Polish National Cancer Registry. Socioeconomic variables in individual voivodeships were assessed based on Polish Social Cohesion Survey for 2015. Spearman's rank correlation coefficient was used to test the association of incidence rates and socioeconomic variables. The significance level was set at p < 0.05 (two-tailed tests).

Results: Statistically significant negative correlation exists between: (1) friend-/neighbour-based social capital and colon and breast cancer, (2) association-based social capital and lung cancer, (3) high religiousness and lung and breast cancer, and (4) income poverty and breast cancer. Statistically significant positive correlation exists between: (1) social isolation, living conditions poverty, poverty resulting from the lack of budget balance, and lung cancer; (2) low/no involvement in religious activity and lung and breast cancer.

Conclusions: Our findings support public health concerns over the implication of socioeconomic environment for cancer.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00038-018-1082-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154031PMC
September 2018

Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015.

PLoS One 2017 5;12(6):e0178764. Epub 2017 Jun 5.

Jan Kochanowski University in Kielce, Kielce, Poland.

Aim: to investigate the drug-class-specific changes in the volume and cost of antidiabetic medications in Poland in 2012-2015.

Methods: This retrospective analysis was conducted based on the National Health Fund database covering an entire Polish population. The volume of antidiabetic medications is reported according to ATC/DDD methodology, costs-in current international dollars, based on purchasing power parity.

Results: During a 4-year observational period the number of patients, consumption of antidiabetic drugs and costs increased by 17%, 21% and 20%, respectively. Biguanides are the basic diabetes medication with a 39% market share. The insulin market is still dominated by human insulins, new antidiabetics (incretins, thiazolidinediones) are practically absent. Insulins had the largest share in diabetes medications expenditures (67% in 2015). The increase in antidiabetic medications costs over the analysed period of time was mainly caused by the increased use of insulin analogues.

Conclusions: The observed tendencies correspond to the evidence-based HTA recommendations. The reimbursement status, the ratio of cost to clinical outcomes and data on the long-term safety have a deciding impact on how a drug is used.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0178764PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459444PMC
September 2017

Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015.

PLoS One 2017 5;12(6):e0178764. Epub 2017 Jun 5.

Jan Kochanowski University in Kielce, Kielce, Poland.

Aim: to investigate the drug-class-specific changes in the volume and cost of antidiabetic medications in Poland in 2012-2015.

Methods: This retrospective analysis was conducted based on the National Health Fund database covering an entire Polish population. The volume of antidiabetic medications is reported according to ATC/DDD methodology, costs-in current international dollars, based on purchasing power parity.

Results: During a 4-year observational period the number of patients, consumption of antidiabetic drugs and costs increased by 17%, 21% and 20%, respectively. Biguanides are the basic diabetes medication with a 39% market share. The insulin market is still dominated by human insulins, new antidiabetics (incretins, thiazolidinediones) are practically absent. Insulins had the largest share in diabetes medications expenditures (67% in 2015). The increase in antidiabetic medications costs over the analysed period of time was mainly caused by the increased use of insulin analogues.

Conclusions: The observed tendencies correspond to the evidence-based HTA recommendations. The reimbursement status, the ratio of cost to clinical outcomes and data on the long-term safety have a deciding impact on how a drug is used.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0178764PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459444PMC
September 2017